Navigation Links
European Society for Medical Oncology and European CanCer Organization join forces
Date:4/9/2008

Lugano, Switzerland and Brussels, Belgium, 9 April 2008: The European Society for Medical Oncology (ESMO) and ECCO - the European CanCer Organisation have united forces to host a co-branded biennial multidisciplinary partnership meeting that will provide the best and most updated scientific data for everyone working in cancer and will also strengthen initiatives aimed at providing all cancer patients with equal access to high-quality cancer care.

The ECCO Congress, which takes place every two years, will become a joint ECCO-ESMO congress, and its scientific committee will be chaired both by ECCO and ESMO. The first congress will be 20-24 September 2009 in Berlin, with subsequent joint congresses being held biennially in the uneven-numbered years.

In the intervening even-numbered years between the ECCO-ESMO congresses, ESMO will continue to hold its own ESMO Congress. In 2008, the 33rd ESMO Congress will take place as planned, 12-16 September, in Stockholm, Sweden.

In addition, ESMOs Board of Directors unanimously voted on 4 April to become a founding member of the new ECCO organisation, composed of European cancer societies, and as a result, ESMO will have a seat on the ECCO Board of Directors. The ECCO Board unanimously accepted the proposal two weeks ago.

ECCO President, Professor Alexander M.M. Eggermont, said he was delighted. ESMO and ECCO have been discussing this for some time now, and we firmly believe that joining forces in this way will benefit all our member organisations, European cancer professionals and, most importantly, cancer patients.

With so much happening in Europe affecting advances in oncology, we need to work together when interacting with European policymakers and industry, so that they take notice, understand and act on our messages. ECCOs mission is to uphold the right of all cancer patients to the best possible treatment and care and to promote interaction between all organisations involved in cancer research, education, treatment and care at the European level. Together with ESMO, I am confident that we will be able to achieve this goal.

ESMO President, Professor Jos Baselga agreed, and added: This uniting of the landscape of European oncology is the result of an agreement on common goals combined with a strong spirit of goodwill and collaboration on all sides. In becoming a founding member of ECCO, we are convinced we will strengthen our ability to represent European oncologists and patients. ESMO is a community of professionals who share the common goal of providing the best possible care for all cancer patients a mission which is in total harmony with ECCOs objectives.

This is a win-win situation for ESMO, ECCO and all of our patients. I am looking forward to liaising closely with Professor Eggermont, not only in supporting medical oncology and cancer treatment by multidisciplinary teams, but also in working towards enhancing European conferences as attractive settings to present research done in Europe and worldwide. Looking ahead, we will combine our efforts to make the 2009 ECCO 15 34th ESMO Congress the best and biggest European cancer congress yet.


'/>"/>

Contact: Emma Mason
wordmason@mac.com
07-711-296-986
ECCO-the European CanCer Organisation
Source:Eurekalert

Related medicine news :

1. FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis
2. Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation
3. IOF recognizes ESCEO European guidance for osteoporosis diagnosis and management
4. More Clinical Data Required to Support European Approval of Desvenlafaxine as a Potential Treatment for Vasomotor Symptoms
5. Gene expression differences between Europeans and Africans affect response to drugs, infections
6. Space sentinels: New tools in space to improve European environment and security policies
7. Boston Scientific Announces First European Implants of New Devices to Treat Heart Failure and Sudden Cardiac Death
8. Specialty European Pharma launches plenaxis in Germany
9. DATATRAK Closes Second Multi-Year Enterprise Agreement with European Clinical Trial Sponsor
10. Mindray to Exhibit at 2008 European Congress of Radiology Annual Meeting
11. European Neuroscience and Society Network tackles neurosocieties head-on
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... 09, 2016 , ... The Bon-Ton Stores, Inc. (NASDAQ: BONT), ... announced it has raised $176,000 to benefit the Breast Cancer Research Foundation, Froedtert ... the University of Iowa, The Lynn Sage Cancer Research Foundation, and Masonic Cancer ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... announced today the introduction of the newly designed, innovative shoulder wrap. The ... cold therapy coverage for the injured arm and shoulder to promote faster healing. ...
(Date:2/9/2016)... ... 09, 2016 , ... i2i Systems, an early innovator and developer of population ... the latest KLAS report, Population Health Management 2015: How Far Can Your Vendor Take ... health management (PHM). The latest KLAS Report, leveraging over 200 user interviews, shines ...
(Date:2/8/2016)... ... 08, 2016 , ... The Federal Laboratory Consortium for Technology ... site houses a wealth of federal resources that businesses can leverage to further ... transfer (T2). As a network of over 300 federal laboratories, the FLC’s mission ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... The Valentine’s Season is famous for gift ... and significant others that they are loved. This year, for more than 5.6 million ... cost - just won't be enough to remind them of the lives they’ve led and ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)...  Insulet Corporation (NASDAQ: PODD ) (Insulet or the ... with its OmniPod ® Insulin Management System, ... appointed to Insulet,s Board of Directors. With his appointment, the ... are independent. --> --> ... experience and a deep knowledge of accounting, financial reporting and ...
(Date:2/9/2016)... -- Sangamo BioSciences, Inc. (NASDAQ: SGMO ), the ... fourth quarter and full year 2015 financial results ... genome editing," said Edward Lanphier, Sangamo,s president and ... technology leads the therapeutic genome editing field and ... move our ground-breaking genome editing programs through IND ...
(Date:2/9/2016)... 2016  Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... quarter and full year financial results on Tuesday, February ... Company management will host a live audio webcast immediately ... to discuss fourth quarter and full year 2015 financial ... guidance for 2016 financial results. www.jazzpharmaceuticals.com .  ...
Breaking Medicine Technology: